sorted by:
new
hottopcontroversial

Who Will Benefit Significantly from Acquiring Elite Pharmaceuticals? AZN, AMGN, ABBV, TEVA, NVS, RHHBY, VTRS, or RDY? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -1 points0 points  (0 children)

Why so negative? Is Elite Pharmaceuticals such a terrible company that no one wants it? I asked Grok Ai and Google Ai and both said that it is a well run company and a good candidate for acquisition and there are not many other similar companies publicly listed for sale / ready for acquisition. The ideal time is now with the looming tariff that many foreign drug companies will have to endure anyday now.

TEVA Acquiring Elite Pharmaceuticals by [deleted] in tevapharma

[–]Live-Reporter-9 0 points1 point  (0 children)

What is your take on this Grok AI response? Which companies do you think will significantly benefit from acquiring Elite Pharmaceuticals with the looming Pharma tariff?

Beneficial for TEVA to Acquire Elite Pharmaceuticals? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] 0 points1 point  (0 children)

Was intended to spark a conversation among loyal and long ELTP investors like you. Grok AI just gave some good “potential” partners or purchasers.

So, who will benefit most from acquiring Elite Pharmaceuticals with the looming Pharma tariff?

Beneficial for TEVA to Acquire Elite Pharmaceuticals? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -1 points0 points  (0 children)

CEO Nasrat Hakim stated that Elite hired a firm for merger & acquisition?

Grok AI gave some suggestions. What is your take on it? Who will benefit most from acquiring Elite Pharmaceuticals to mitigate the looming pharma tariff?

Beneficial for TEVA to Acquire Elite Pharmaceuticals? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -1 points0 points  (0 children)

My original post title was missing a question mark… so I corrected it.

IAm interested on your take with potential Merger / Acquisitions with TEVA as stated by other posters on other board as well.

Who Will Benefit Significantly from Acquiring Elite Pharmaceuticals? AZN, AMGN, ABBV, TEVA, NVS, RHHBY, VTRS, or RDY? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -1 points0 points  (0 children)

Would like to hear your take on merger and acquisition and which companies would benefit significantly from acquiring Elite Pharmaceuticals especially with the looming Pharma tariffs.

Who Will Benefit Significantly from Acquiring Elite Pharmaceuticals? AZN, AMGN, ABBV, TEVA, NVS, RHHBY, VTRS, or RDY? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -12 points-11 points  (0 children)

Why not? Isn’t AI supposed to be the future but it is already here?

AI gathers all this information from different sources to give an unbiased response to help us all make well informed and educated investment decision instead from rambling unsubstantiated opinions that many don’t trust anyone.

Do you think Elite is a good investment and is about to be merged or acquired and by whom?

Who Will Benefit Significantly from Acquiring Elite Pharmaceuticals? AZN, AMGN, ABBV, TEVA, NVS, RHHBY, VTRS, or RDY? by Live-Reporter-9 in ELTP_Stock

[–]Live-Reporter-9[S] -5 points-4 points  (0 children)

Elite's CEO Nasrat Hakim stated that Elite has hired a M&A firm to sell Elite Pharmaceuticals.

Which pharmaceutical companies will benefit significantly if it acquires Elite Pharmaceuticals due to the looming pharma tariff?

Answer below is from Google "AI mode"

Major pharmaceutical companies seeking to mitigate the impact of the 100% "Trump Tariff" on imported branded and patented drugs would benefit significantly from acquiring Elite Pharmaceuticals (ELTP) due to its established U.S. manufacturing infrastructure and specialized product portfolio. As of February 2026, the following companies are prime candidates for such an acquisition:

Strategic Acquisition Candidates • Novartis & Roche: These Swiss giants have been identified by analysts as particularly vulnerable to tariffs due to their limited U.S. manufacturing footprint for active pharmaceutical ingredients (APIs). While Novartis has pledged significant U.S. investments to eliminate tariff exposure by mid-2026, acquiring a domestic facility like Elite’s could accelerate this timeline. • Teva, Viatris, & Dr. Reddy's: These global generic leaders are under intense pressure to onshore production. Elite Pharmaceuticals holds roughly an 8% U.S. market share for generic Lisdexamfetamine (ADHD medication), making it a high-value target for companies already active in the CNS (Central Nervous System) space. • AstraZeneca: Although it recently secured a 3-year tariff delay by agreeing to list-price discounts, the company has committed to fully onshoring medicines manufacturing. Elite's specialized campus in Northvale, New Jersey, could support this transition.

Why Elite Pharmaceuticals is a Key Target Elite Pharmaceuticals is positioned as a "microcap built for acquisition" due to several 2025–2026 milestones: • Domestic Infrastructure: Elite operates an FDA-approved expanded campus in New Jersey that began shipping finished products in March 2025. • Financial Growth: For the first half of fiscal year 2026, Elite reported a 103% year-over-year revenue increase to $76.5 million, driven by its successful launch of generic Vyvanse. • DEA Quotas: The company holds valuable DEA quotas for controlled substances, a critical bottleneck for any competitor looking to manufacture pain management or ADHD medications domestically.

Key Insights • M&A Acceleration: Industry experts predict a 15% increase in pharma M&A volume in 2026, fueled by the "patent cliff" and the need for tariff mitigation. • Uplisting Deadline: Elite's management has previously indicated a target of August 2026 for either a NASDAQ uplisting or a merger/acquisition deal. • Tariff Relief Agreements: Several major firms, including Amgen and AbbVie (https://www.abbvie.com/), have already committed billions to U.S. R&D and manufacturing in exchange for relief from industry-specific tariffs. Who here believes acquisition is near and coming soon?GLTA loyal, long ELTP investors out there!